• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Corline Biomedical

17.50 SEK+1.16 %15/7 17:28
Less than 1K followers

CLBIO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+1.16 %
-1.13 %
+7.03 %
-4.37 %
+6.71 %
+35.66 %
+10.06 %
+39.44 %
+76.92 %

Corline Biomedical is active in the pharmaceutical industry. The company works with the substance heparin and has developed a portfolio of drug candidates for use in connection with organ and cell transplantation. The company sells its proprietary product CHS™ to medical technology customers, and is developing Renaparin® for use in regenerative medicine and organ transplantation. The headquarters are located in Uppsala.

Read more
Market cap
457.33M SEK
Turnover
25.17K SEK
Revenue
7.65M
EBIT %
-192.81 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/8
2026

Interim report Q2'26

16/11
2026

Interim report Q3'26

18/2
2027

Annual report '26

Regulatory press release2026-07-02 16:32

5-årsuppföljning stödjer säkerhet och indikerar positiv behandlingseffekt av Renaparin®

Corline Biomedical
Regulatory press release2026-05-12 20:50

Kommuniké från årsstämma i Corline Biomedical AB (publ)

Corline Biomedical
Press release2026-05-11 10:16

Redeye: Corline Biomedical (Q1 Review): Encouraging signs of commercial acceleration

Corline Biomedical

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release2026-05-08 08:45

Corline Biomedical AB offentliggör delårsrapport för perioden januari till mars 2026

Corline Biomedical
Regulatory press release2026-04-21 17:18

Corline Biomedical publicerar årsredovisning för 2025

Corline Biomedical
Regulatory press release2026-04-07 14:36

KALLELSE TILL ÅRSSTÄMMA I CORLINE BIOMEDICAL AB (PUBL)

Corline Biomedical
Press release2026-02-18 11:21

Redeye: Corline Biomedical Q4 (Review): Case intact, but sales ramp-up needed to restore market confidence

Corline Biomedical
Regulatory press release2026-02-17 08:35

Corline Biomedical AB offentliggör bokslutskommuniké för perioden januari till december 2025

Corline Biomedical
Regulatory press release2026-01-09 08:44

CorlineCorline Biomedical stärker samarbetet med Kardium – genomför riktad emission och upptar lån från Kardium för att mångfaldiga produktionskapaciteten

Corline Biomedical
Press release2025-11-26 16:31

Förändringar i ersättningssystemet i USA möjliggör breddning av PFA-marknaden

Corline Biomedical
Press release2025-11-19 08:25

Redeye: Corline Biomedical Q3 (Review) - Sales growth incoming

Corline Biomedical
Regulatory press release2025-11-18 08:45

Corline Biomedical AB offentliggör delårsrapport för perioden januari till september 2025

Corline Biomedical
Regulatory press release2025-10-08 16:14

Corline Biomedical genomför en riktad emission om 23 MSEK

Corline Biomedical
Press release2025-10-01 17:30

Kardium har inlett kommersialiseringen av Globe-systemet i USA

Corline Biomedical
Regulatory press release2025-09-30 11:52

Corline tecknar tioårigt licens- och leveransavtal med bedömt värde om cirka 2 miljarder kronor

Corline Biomedical
Press release2025-09-02 10:29

Redeye: Corline Biomedical - Kardium receives FDA approval

Corline Biomedical
Regulatory press release2025-09-01 10:22

Kardiums Globe-kateter med CHS™-coatning erhåller FDA-godkännande

Corline Biomedical
Press release2025-08-27 11:54

Redeye: Corline Biomedical Q2 - Kardium’s Globe system nearing launch

Corline Biomedical
Regulatory press release2025-08-26 08:45

Corline Biomedical AB offentliggör delårsrapport för perioden januari till juni 2025

Corline Biomedical
Press release2025-07-02 15:11

Corlines kund Kardium genomför finansiering om 250 miljoner USD för lanseringen av Globe®

Corline Biomedical